Cite
HARVARD Citation
Ye, D. et al. (n.d.). 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for immunotherapy of cancer. p. A85. [Online].